Second pharma deal further validates Interprotein's discovery technology
This article was originally published in Scrip
The Japanese drug discovery venture Interprotein Corp has entered into its second agreement with a major pharma firm in as many months, this time with Takeda for the discovery and optimisation of small molecule inhibitors of protein-protein interaction.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.